Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies.

ABSTRACT: Melanoma possesses invasive metastatic growth patterns and is one of the most aggressive types of skin cancer. In 2021, it is estimated that 7180 deaths were attributed to melanoma in the United States alone. Once melanoma metastasizes, traditional therapies are no longer effective. Instead, immunotherapies, such as ipilimumab, pembrolizumab, and nivolumab, are the treatment options for malignant melanoma. Several biomarkers involved in tumorigenesis have been identified as potential targets for molecularly targeted melanoma therapy, such as tyrosine kinase inhibitors (TKIs). Unfortunately, melanoma quickly acquires resistance to these molecularly targeted therapies. To bypass resistance, combination treatment with immunotherapies and single or multiple TKIs have been employed and have bee

SUBMITTER: Rager T 

PROVIDER: S-EPMC9367420 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature